CeriBellCBLL stock score: 51/100
$25.75 · +0.47% · Scored Nov 19, 2026
- Technical
- 54
- Fundamental
- 50
- News
- 52
The reading
CeriBell (CBLL) scores 51 out of 100, which reads neutral, higher than 51% of Healthcare stocks and 47% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 50, technicals 54.
Among the fundamentals, Quick Ratio at 100 and Current Ratio at 100 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 43 and contrarian oscillators 57.
News sentiment is neutral at 52; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 50 to 56, and it is down 5 points over the period.
About CeriBell
CeriBell (CBLL) is a medical technology company that makes a point-of-care electroencephalography system for detecting seizures in hospital patients. Its system combines a headband with electrodes, which nurses and other staff can place quickly without a specialized EEG technician, a portable recorder and cloud-based software. Its Clarity algorithm uses artificial intelligence to analyze brain activity continuously, estimate seizure burden and alert care teams, while neurologists can review recordings remotely. The FDA has cleared the system for use across patient ages, from newborns through adults, and the company also markets it for delirium assessment. CeriBell sells mainly to hospitals for use in intensive care units and emergency departments. It earns money from subscription fees for access to its system and software and from sales of single-use headbands, so revenue grows as more hospitals adopt the system and use it on more patients.
CeriBell competes with conventional EEG systems from companies such as Natus Medical and Nihon Kohden, along with neurology monitoring services and other rapid EEG developers. Its edge rests on fast setup by bedside staff, an AI algorithm with FDA clearances and published clinical studies supporting its use. Investors who follow CBLL stock tend to watch revenue growth, the number of active hospital accounts and headband usage. Gross margin and operating losses are closely followed. Reimbursement, expansion into new indications and patient groups, competition and cash runway are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward CBLL’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
50Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
Current assets divided by current liabilities: the ability to pay short-term bills.
5-year revenue growth analyzes long-term sales trajectory and consistency.
Holding it back
Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.
Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.
5-year earnings growth evaluates long-term profit trajectory and consistency.
38 weighted scorers; 1 had no data today and are left out rather than counted as zero.
Technical · daily
51Pulling it up
The price change over the last 52 weeks.
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
S&P 500 52-week comparison evaluates the stock's annual performance relative to the broader market.
Holding it back
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
Percentage Price Oscillator shows the difference between two moving averages as a percentage.
- VWAP8
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 52
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 43 | 1 |
| Daily | 51 | 3 |
| Weekly | 64 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 51 |
| Nov 18, 2026 | 51 |
| Nov 15, 2026 | 51 |
| Nov 14, 2026 | 51 |
| Nov 13, 2026 | 51 |
| Nov 12, 2026 | 50 |
| Nov 11, 2026 | 56 |
| Nov 10, 2026 | 56 |
| Nov 7, 2026 | 53 |
| Nov 6, 2026 | 53 |
| Nov 5, 2026 | 53 |
| Nov 4, 2026 | 52 |
| Nov 3, 2026 | 54 |
| Nov 2, 2026 | 54 |
| Nov 1, 2026 | 53 |
| Oct 30, 2026 | 53 |
| Oct 29, 2026 | 55 |
| Oct 27, 2026 | 55 |
| Oct 26, 2026 | 54 |
| Oct 25, 2026 | 54 |
| Oct 24, 2026 | 54 |
| Oct 23, 2026 | 54 |
| Oct 22, 2026 | 55 |
| Oct 21, 2026 | 55 |
| Oct 20, 2026 | 55 |
| Oct 19, 2026 | 55 |
| Oct 18, 2026 | 54 |
| Oct 17, 2026 | 54 |
| Oct 16, 2026 | 54 |
| Oct 15, 2026 | 55 |
| Oct 14, 2026 | 55 |
| Oct 13, 2026 | 55 |
| Oct 12, 2026 | 56 |
| Oct 11, 2026 | 53 |
| Oct 10, 2026 | 53 |
| Oct 9, 2026 | 53 |
| Oct 8, 2026 | 52 |
| Oct 7, 2026 | 53 |
| Oct 6, 2026 | 55 |
| Oct 5, 2026 | 55 |
| Oct 4, 2026 | 53 |
| Oct 3, 2026 | 53 |
| Oct 2, 2026 | 53 |
| Oct 1, 2026 | 52 |
| Sep 30, 2026 | 54 |
| Sep 29, 2026 | 55 |
| Sep 28, 2026 | 55 |
| Sep 27, 2026 | 54 |
| Sep 26, 2026 | 54 |
| Sep 25, 2026 | 54 |
| Sep 24, 2026 | 55 |
| Sep 23, 2026 | 55 |
| Sep 22, 2026 | 55 |
| Sep 21, 2026 | 55 |
| Sep 20, 2026 | 54 |
| Sep 19, 2026 | 54 |
| Sep 18, 2026 | 54 |
| Sep 17, 2026 | 55 |
| Sep 16, 2026 | 55 |
| Sep 15, 2026 | 56 |
| Sep 14, 2026 | 55 |
| Sep 13, 2026 | 54 |
| Sep 12, 2026 | 54 |
| Sep 11, 2026 | 54 |
| Sep 10, 2026 | 53 |
| Sep 9, 2026 | 55 |
| Sep 8, 2026 | 55 |
| Sep 7, 2026 | 56 |
| Sep 6, 2026 | 56 |
| Sep 5, 2026 | 56 |
| Sep 4, 2026 | 56 |
| Sep 2, 2026 | 56 |
| Sep 1, 2026 | 56 |
| Aug 31, 2026 | 56 |
| Aug 30, 2026 | 56 |
| Aug 29, 2026 | 55 |
| Aug 28, 2026 | 56 |
| Aug 27, 2026 | 55 |
| Aug 26, 2026 | 55 |
| Aug 25, 2026 | 55 |
| Aug 24, 2026 | 55 |
| Aug 23, 2026 | 56 |
Key facts
- Market cap
- $1.0B
- Sector
- Healthcare
- Industry
- Medical Devices
- Beta
- 0.86
- Risk grade (1–10)
- 7
- Next earnings
- Nov 3, 2026
Medical Device peers
| Company | Market cap | Score |
|---|---|---|
| NVCR NovoCure | $1.2B | 44 |
| TNDM Tandem Diabetes Care | $1.2B | 38 |
| SIBN SI-BONE | $1.1B | 59 |
| ATEC Alphatec | $1.1B | 52 |
| IART Integra LifeSciences Holdings | $1.1B | 43 |
| IRMD IRADIMED | $1.0B | 66 |
Questions
What is CBLL's stock rating today?
CBLL scores 51/100 (Neutral) as of Nov 19, 2026: technical 54, fundamental 50, and news sentiment 52, which is shown but not counted. Scores are recomputed every night.
What does CeriBell do?
CeriBell (CBLL) is a medical technology company that makes a point-of-care electroencephalography system for detecting seizures in hospital patients. Its system combines a headband with electrodes, which nurses and other staff can place quickly without a specialized EEG technician, a portable recorder and cloud-based software.
Is CBLL stock a buy?
The score is not a buy or sell recommendation. A 51 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the CBLL score calculated?
100 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/cbll/"><img src="https://stocksscores.com/stocks/cbll/badge.svg" alt="CBLL stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/cbll/)